Skip to main content

Research Repository

Advanced Search

Outputs (4)

Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial (2023)
Presentation / Conference
Roffe, C., Warusevitane, A., Smith, C., Dixit, A., Sprigg, N., Ogollah, R., …Bath, P. (2023, October). Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial. Poster presented at 15th World Stroke Congress, Toronto, Canada

The research study is designed to assess a treatment which might prevent pneumonia and improve survival in patients that have had a stroke. Pneumonia is a major cause of death after stroke and delays recovery in survivors. The most important cause o... Read More about Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial.

THE METOCLOPRAMIDE FOR AVOIDING PNEUMONIA AFTER STROKE (MAPS-2) TRIAL: A SINGLE-BLIND RCT OF METOCLOPRAMIDE FOR THE PREVENTION OF PNEUMONIA IN PATIENTS WITH DYSPHAGIA AFTER STROKE (2021)
Presentation / Conference
Roffe, C., Bath, P., Warusevitane, A., Smith, C., Dixit, A., Sprigg, N., …Ogollah, R. (2021, November). THE METOCLOPRAMIDE FOR AVOIDING PNEUMONIA AFTER STROKE (MAPS-2) TRIAL: A SINGLE-BLIND RCT OF METOCLOPRAMIDE FOR THE PREVENTION OF PNEUMONIA IN PATIENTS WITH DYSPHAGIA AFTER STROKE. Presented at UK Stroke Forum 2021, Virtual

An empirical evaluation of the impact of missing data on treatment effect (2015)
Presentation / Conference
Royes, J., Sim, J., Ogollah, R., & Lewis, M. (2015, November). An empirical evaluation of the impact of missing data on treatment effect. Poster presented at 3rd International Clinical Trials Methodology Conference, Glasgow, UK

Objectives Missing data represent a potential source of bias in randomized clinical trials (RCTs). A simple approach that makes use of the responses subsequently obtained via reminder is proposed to assess the validity of the inferences from a missi... Read More about An empirical evaluation of the impact of missing data on treatment effect.